이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Cytogen 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Byung-Hee Jeon

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	15.0%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

업데이트 없음

Recent updates

Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?

Mar 23

What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition

Jan 25

Is Cytogen (KOSDAQ:217330) Using Too Much Debt?

Dec 03

CEO

Byung-Hee Jeon (65 yo)

no data

테뉴어

Mr. Jeon Byung-Hee serves as CEO and Representative Director at Cytogen, Inc.

Cytogen 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Recent updates

Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors

Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.

New minor risk - Share price stability

Third quarter 2023 earnings released: ₩149 loss per share (vs ₩149 loss in 3Q 2022)

New minor risk - Shareholder dilution

New major risk - Financial position

Cytogen, Inc. announced that it expects to receive KRW 30 billion in funding

Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?

New 90-day high: ₩61,900

What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition

New 90-day high: ₩60,300

New 90-day high: ₩42,000

New 90-day high: ₩40,000

Is Cytogen (KOSDAQ:217330) Using Too Much Debt?

New 90-day high: ₩34,550

New 90-day high: ₩34,000

Cytogen, Inc. announced that it expects to receive KRW 10 billion in funding

Cytogen, Inc. has withdrawn its IPO.

New 90-day low - ₩11,000

CEO

테뉴어